| Literature DB >> 27293892 |
Debajit Bhowmick1, Kaushik Bhar1, Sanjaya K Mallick2, Subhadip Das3, Nabanita Chatterjee3, Tuhin Subhra Sarkar1, Rajarshi Chakrabarti1, Krishna Das Saha3, Anirban Siddhanta1.
Abstract
Entities:
Year: 2016 PMID: 27293892 PMCID: PMC4886052 DOI: 10.1155/2016/3137010
Source DB: PubMed Journal: Biochem Res Int
Figure 1Cytotoxic effect of para-phenylenediamine and ortho-phenylenediamine (o-PD) on melanoma cells. A375 (a) and B16-F10 (b) cells grown in a 96-well (5000 cells in each well) plate were treated with p-PD of indicated concentrations for 16, 24, and 48 hours at 37°C. (c) In a similar manner, A375 cells were also treated with o-PD for 24 and 48 hours with indicated concentrations. Four wells were used for each concentration in every time point. One set of untreated cells (0.1% DMSO) was kept as control for each time point. The absorbance reading (OD) for each set obtained from the microplate reader was used to compute the percent change in viable cell in treated sets over respective controls using the expression {(ODControl − ODExperimental) × 100/ODControl}. The % viable cell over control was plotted against respective concentrations of p-PD. Error bars represent SD; n = 4.
Figure 2Body weight gain of the mice treated with or without p-PD. (a) Effect of p-PD on tumour development in mice. Initially, right flanks of two sets of Swiss-Albino mice were given subcutaneous injection with only PBS (A) and B16-F10 cells (B) as mentioned in the Materials and Methods. These mice were kept for 2 weeks until visible tumour in the set (B) is formed. The mice from set (B) were divided into three groups: one (C) was treated with 2 and the other (D) was treated with 4 mg/kg of p-PD for 10 days. One (B) set was left untreated as control. Photographs of representative mouse from each set are shown here. Each set comprised 6 mice except for set (B) where initially 18 mice were used for the experiment. (b) Body weights of untreated mice (set (A) above) (■), mice treated with 4 mg/kg of p-PD (⧫), mice having tumour (- - -) (set (B)), and mice having tumour treated with 2 (▲) (set (C)) and 4 (∙) mg/kg (set (D)) of p-PD are plotted against the days of treatment. Arrows indicate the time of peritoneal p-PD administration. Error bars represent SD; n = 6. ∗ indicates the two-tailed p value ≤ 0.018. By conventional criteria, this difference is considered to be statistically significant.
Effect of p-PD treatment on body weight with major organ weight in mice.
| Treatment | Initial body weight (g) | Final body weight (g) | Final heart weight (g) | Final lung weight (g) | Final liver weight (g) | Final kidney weight (g) | Final spleen weight (g) |
|---|---|---|---|---|---|---|---|
| Control (vehicle only) | 22 ± 0.33 | 25 ± 0.06 | 0.16 ± 0.02 | 0.16 ± 0.06 | 1.7 ± 0.04 | 0.35 ± 0.12 | 0.26 ± 0.03 |
| Treatment dose 1 | 25 ± 0.09 | 29 ± 0.11 | 0.16 ± 0.04 | 0.13 ± 0.09 | 1.92 ± 0.03 | 0.38 ± 0.06 | 0.27 ± 0.03 |
| Treatment dose 2 | 20 ± 0.04 | 24 ± 0.12 | 0.15 ± 0.06 | 0.18 ± 0.02 | 1.57 ± 0.08 | 0.32 ± 0.05 | 0.24 ± 0.04 |
Dose 1 and dose 2: p-PD 5 and 10 mg/kg/3 days, respectively.
Values are expressed as mean ± SEM (n = 10).
Effect of p-PD treatment on serum biochemical parameters of mice.
| Treatment | SGOT (IU/dL) | SGPT (IU/dL) | SALP (IU/dL) | Bilirubin (mg/dL) | ALT (IU/dL) | AST (IU/dL) | ALP (IU/dL) | Urea (mg/dL) | Uric acid (mg/dL) | Creatinine (mg/dL) |
|---|---|---|---|---|---|---|---|---|---|---|
| Control (vehicle only) | 43 ± 11.01 | 35 ± 5.22 | 84 ± 8.33 | 1.0 ± 0.12 | 46 ± 5.23 | 95 ± 14.33 | 286 ± 7.36 | 155 ± 9.36 | 7 ± 9.33 | 1.0 ± 1.22 |
| Treatment dose 1 | 41 ± 6.02 | 34 ± 4.12 | 89 ± 3.63 | 1.0 ± 1.32 | 47 ± 6.03 | 97 ± 16.33 | 296 ± 9.36 | 157 ± 11.23 | 7 ± 14.36 | 1.0 ± 1.88 |
| Treatment dose 2 | 45 ± 6.14 | 37 ± 9.11 | 86 ± 9.32 | 1.0 ± 2.33 | 43 ± 9.54 | 92 ± 3.63 | 289 ± 9.36 | 165 ± 18.33 | 6 ± 9.36 | 1.0 ± 1.22 |
Dose 1 and dose 2: p-PD 5 and 10 mg/kg/3 days, respectively.
Values are expressed as mean ± SEM (n = 10).
Figure 3p-PD mediates apoptosis in melanoma cells. (a) A375 cells were treated with p-PD as indicated. After treatment, cells were lysed with protein loading buffer (Materials and Methods). 30 μg of total protein lysate was loaded in each lane and subjected to western blot and probed for activation of PARP. Cells that were not treated with p-PD (0) but with 0.1% DMSO served as control (lanes 1, 5, and 9). These blots are representative of three independent analyses. β-actin is used as a loading control for all time points. (b) Both A375 and B16-F10 cells were treated for 48 hours with indicated amounts of p-PD and were subjected to flow cytometry analysis using Annexin V-FITC assay. DAPI was used as the DNA stain.
Quantification of apoptosis.
| Cell status | Control | 24 hours | Control | 48 hours | ||||
|---|---|---|---|---|---|---|---|---|
| p-PD ( | p-PD ( | |||||||
| 20 | 40 | 100 | 20 | 40 | 100 | |||
| A375 | ||||||||
| Livea | 92 ± 1 | 90 ± 1.3 | 89 ± 4.34 | 81 ± 0.34 | 91 ± 0.85 | 59 ± 1.3 | 42 ± 0.23 | 36 ± 0.6 |
| Early apoptosisa | 3 ± 0.2 | 3 ± 0.5 | 5 ± 0.3 | 11 ± 0.19 | 6 ± 0.93 | 11 ± 0.4 | 17 ± 0.2 | 21 ± 0.58 |
| Late apoptosisa | 4 ± 0.4 | 6 ± 0.4 | 6 ± 0.3 | 7 ± 0.43 | 2 ± 0.1 | 27 ± 0.3 | 39 ± 0.5 | 40 ± 0.86 |
| Sub-G0/G1b | 10 ± 1.8 | 11 ± 0.5 | 15 ± 2.2 | 24 ± 4 | 10 ± 2.8 | 38 ± 6.4 | 39 ± 5.1 | 50 ± 7.3 |
|
| ||||||||
| B16-F10 | ||||||||
| Livea | 87 ± 6.8 | 75 ± 7.4 | 73 ± 6.6 | 71 ± 6.8 | 92 ± 4.1 | 44 ± 5.3 | 36 ± 2.4 | 8 ± 1 |
| Early apoptosisa | 6 ± 0.3 | 16 ± 3.2 | 17 ± 3.4 | 17 ± 2.2 | 4 ± 0.8 | 32 ± 4.1 | 36 ± 3.1 | 42 ± 1.9 |
| Late apoptosisa | 5 ± 0.8 | 7 ± 2 | 9 ± 3 | 11 ± 1.6 | 4 ± 0.6 | 21 ± 1.9 | 23 ± 2.5 | 43 ± 1.8 |
| Sub-G0/G1b | 1 ± 1.5 | 4 ± 1 | 6 ± 1.4 | 10 ± 1.2 | 2 ± 0.1 | 22 ± 3.1 | 55 ± 4.4 | 60 ± 2.9 |
aThe percent cell numbers of early and late apoptotic stages were determined from the respective dot plots (one such plot is shown in Figure 3(b)).
bThe sub-G0/G1 cells were estimated using standard cell cycle analysis by flow cytometry.
All the sets were performed in triplicate.
p-PD treated and untreated (control) A375 andB16-F10 cells were subjected to Annexin V-FITC assay as mentioned in the Materials and Methods.
Figure 4Cell cycle arrest at S phase imposed by p-PD. (a) Cell cycle distribution of A375 cells treated with p-PD as indicated was determined by PI staining using flow cytometry. The number of cells in S phase for each set was determined and plotted against indicated concentration of p-PD. Error bars represent SD; n = 3. (b) Flow cytometric analysis of BrdU incorporation by A375 cells treated with indicated concentrations of p-PD. The BrdU positive cell cultures at the S phase are gated in pink. Respective percent cell numbers are shown next to the gated cell clusters representing cell cycle phases.
Figure 5p-PD activates extrinsic apoptotic pathways earlier than the intrinsic ones in human melanoma cells. (a) A375 cells were treated with p-PD as indicated. Cells treated for 6 and 24 hours were lysed with protein loading buffer (Materials and Methods). 30 μg of total protein lysate (same as described in Figure 3(a)) was loaded in each lane and subjected to western blot and probed for activated caspase 3, activated caspase 8, activated caspase 9, and Bid as indicated. Arrow and “⧫” indicate the cleaved fragments of caspase 8 and caspase 9, respectively. Cells that were not treated with p-PD (0) but with 0.1% DMSO served as controls. (b) Cells treated for 48 hours were lysed and analysed by western blot as mentioned above by probing with antibodies against active caspase 9 and Bid. “⧫” indicates both cleaved fragments of caspase 9. β-actin is used as a loading control for both panels. These blots are representative of three independent analyses.
Figure 6Caspase 8 inhibitor decreases the number of dead A375 cells. Cells were pretreated with the inhibitors of caspase 8 (a), caspase 9 (b), and PAN caspase (c) for two hours and subsequently treated with p-PD for 24 hours. Percent change in viable cells in sets with inhibitor pretreatment was computed as described in the Materials and Methods. The net protective effect (‡) is either the |value of white bar + value of black bar| or the decrease in dead cell number as denoted by ▲. By conventional criteria, this difference is considered to be extremely statistically significant. ∗ indicates the two-tailed p value ≤ 0.005. Each set was performed in triplicate.
Figure 7p-PD depolarizes mitochondrial membrane potential of both melanoma cells. p-PD treated (as indicated for two hours) and untreated (0 μg/mL) melanoma cells were subjected to JC 1 staining for the measurement of MMP. For both cell lines, cell clusters which are high in PE fluorescence are gated in the top of each dot plot (red and green for B16-F10 and A375 cells, resp.) presenting the healthy cell population. Cell clusters that are gated for low PE fluorescence in the bottom part of each dot plot (green and blue for B16-F10 and A375 cells, resp.) are representing the cells with depolarized mitochondria. Cell percentage values of the gated population are stating the effect of p-PD in the polarization of mitochondria. One piece of the representative experimental data is shown here. Each set was performed in triplicate.
Figure 8p-PD treatment increases the level of ROS in A375 cells. Control cells and cells treated with p-PD for 16 hours were subjected to DCFH-DA stain. Flow cytometric analyses of the stained cells were done as described in the Materials and Methods. One experimental data set is shown here. The percentage change of ROS was calculated using the expression (ROSExperiment − ROSControl) × 100/ROSControl. Each set was performed in triplicate.
Change in the biochemical parameters of oxidative stress induced by 100 µg/mL of p-PD for 24 hours on A375 cells.
| Glutathione reductase | Catalase | GSH | GSH : GSSG | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| p-PD ( | % change | p-PD ( | % change | p-PD ( | % changea | p-PD ( | % changea | ||||
| Cont. | 100 | Cont. | 100 | Cont. | 100 | Cont. | 100 | ||||
| 12 ± 1.5 | 17 ± 0.5 | 39 ± 8.6 | 5 ± 0.3 | 6 ± 0.2 | 22 ± 2 | 19.2 ± 0.7 | 5.9 ± 1.9 | 70 ± 13 | 62 ± 26 | 12 ± 4 | 80 ± 9 |
aThese changes indicate percent decrease of the respective parameters in the treated samples. Each set of data is averaged from three different experiments.
Oxidative stress was measured using the standard parameters such as reduced GSH amount, GSH : GSSG, and activity of glutathione reductase and catalase. Parameters were measured as described in Section 2.5. We used control cells and cells treated for 24 hours with 100 µg/mL of p-PD for these experiments. GSH was expressed as nmol mg−1 protein; catalase and glutathione reductase activities were expressed as nmol min−1 mg−1 protein.
Effect of NAC and GSH pretreatment on ROS generation and apoptosis in A375 cells.
| p-PD ( | % decrease in ROS | % drop in apoptosis | ||
|---|---|---|---|---|
| NAC (10 mM) pretreatment | GSH (5 mM) pretreatment | NAC (10 mM) pretreatment | GSH (5 mM) pretreatment | |
| 0 | 34 ± 3.5 | −6 ± 0.9 | 0 | 0 |
| 20 | 31 ± 2.6 | 34 ± 1.4 | 63 ± 4.7 | 41 ± 5.6 |
| 40 | 66 ± 4.5 | 29 ± 2 | 47 ± 4 | 18 ± 0.2 |
| 100 | 25 ± 1.2 | 6 ± 0.3 | 41 ± 2.1 | 44 ± 3 |
A375 cells were divided into 2 groups: one was pretreated with NAC or GSH for 1 hour and then treated with p-PD for 16 hours and the other was treated with only p-PD. ROS values and apoptotic cell numbers were quantified at the end of p-PD exposure as mentioned in the Materials and Methods. Percentage changes in ROS and apoptosis were calculated as follows: % change = {(only p-PD value − respective pretreatment value)/respective pretreatment value} × 100. Values are representative of three independent experiments.